Efficacy

Alunbrig (brigatinib) for Lung Cancer

Alunbrig (brigatinib) is a targeted therapy approved for the treatment of non-small cell lung cancer (NSCLC) with a specific mutation. It is particularly effective in patients who have anaplastic lymphoma kinase (ALK)-positive NSCLC and who have progressed on or are intolerant to crizotinib, which is another ALK inhibitor. Clinical trials have demonstrated that brigatinib has significant efficacy in this patient population. The ALTA-1L trial, a pivotal study for brigatinib, showed a prolonged progression-free survival in patients treated with brigatinib compared to crizotinib, highlighting its potency against ALK-positive NSCLC.

Brigatinib's efficacy is also notable for its intracranial activity. Patients with ALK-positive NSCLC often develop brain metastases, and brigatinib has shown a high degree of effectiveness in controlling disease progression in the central nervous system. This is particularly important for patient quality of life and overall survival, as effective control of brain metastases is a critical aspect of lung cancer treatment.

Cyramza (ramucirumab) for Lung Cancer

Cyramza (ramucirumab) is a monoclonal antibody that targets the vascular endothelial growth factor receptor 2 (VEGFR2), which is involved in the formation of new blood vessels (angiogenesis). In the context of lung cancer, Cyramza is approved for use in combination with docetaxel for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose cancer has progressed during or after platinum-based chemotherapy. Clinical trials have shown that this combination extends overall survival and progression-free survival when compared to docetaxel alone, offering an additional option for patients with advanced NSCLC.

The efficacy of Cyramza in lung cancer was demonstrated in the REVEL trial, a phase III study that included a broad patient population with different histologies of NSCLC. The results indicated an improvement in overall survival across subgroups, including those with squamous and non-squamous NSCLC. Cyramza's ability to inhibit angiogenesis makes it a valuable component of combination therapy for lung cancer, particularly in the second-line setting where treatment options are limited.